Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.
Several other equities analysts also recently commented on AMPH. Jefferies Financial Group assumed coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, July 25th. They issued a “buy” rating and a $70.00 price objective on the stock. Piper Sandler upped their price objective on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a report on Wednesday, August 9th.
Check Out Our Latest Report on AMPH
Amphastar Pharmaceuticals Stock Performance
NASDAQ AMPH traded down $1.31 on Friday, hitting $45.99. 520,846 shares of the stock were exchanged, compared to its average volume of 395,168. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.53 and a quick ratio of 1.11. The business’s fifty day moving average is $53.60 and its 200 day moving average is $48.32. Amphastar Pharmaceuticals has a 52 week low of $26.76 and a 52 week high of $67.66. The company has a market capitalization of $2.22 billion, a PE ratio of 23.58 and a beta of 0.84.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.06. Amphastar Pharmaceuticals had a net margin of 18.85% and a return on equity of 20.12%. The firm had revenue of $145.71 million for the quarter, compared to analyst estimates of $137.20 million. Research analysts anticipate that Amphastar Pharmaceuticals will post 2.5 EPS for the current fiscal year.
Insider Activity at Amphastar Pharmaceuticals
In related news, CFO William J. Peters sold 60,743 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total value of $3,143,450.25. Following the transaction, the chief financial officer now directly owns 101,360 shares in the company, valued at $5,245,380. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 60,743 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $51.75, for a total transaction of $3,143,450.25. Following the sale, the chief financial officer now directly owns 101,360 shares in the company, valued at $5,245,380. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael A. Zasloff sold 12,759 shares of the stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $57.22, for a total transaction of $730,069.98. Following the sale, the director now owns 33,826 shares in the company, valued at $1,935,523.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,318 shares of company stock worth $5,509,514. Corporate insiders own 28.40% of the company’s stock.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
Large investors have recently bought and sold shares of the company. West Tower Group LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth about $39,000. Point72 Middle East FZE bought a new position in shares of Amphastar Pharmaceuticals in the fourth quarter worth about $50,000. Pacer Advisors Inc. bought a new position in shares of Amphastar Pharmaceuticals in the second quarter worth about $59,000. Point72 Hong Kong Ltd bought a new position in shares of Amphastar Pharmaceuticals in the first quarter worth about $74,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Amphastar Pharmaceuticals by 206.9% in the first quarter. Tower Research Capital LLC TRC now owns 1,998 shares of the company’s stock worth $75,000 after acquiring an additional 1,347 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
(Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amphastar Pharmaceuticals wasn’t on the list.
While Amphastar Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Source link
credite